Phase 3 trial shows linerixibat improves cholestatic pruritus in patients with primary biliary cholangitis, indicating potential treatment benefits.
Background and Aims: Cholestatic pruritus is common, debilitating and undertreated in patients with primary biliary cholangitis (PBC). Here, we describe the results of GLISTEN (NCT04950127), a Phase 3 study investigating the efficacy and safety of the ileal bile acid transporter inhibitor linerixibat for pruritus in PBC.
No takes yet. Share an insight, caveat, or question.
Hirschfield et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: